Share on StockTwits

Amicus Therapeutics (NASDAQ:FOLD) VP Jayne Gershkowitz sold 5,000 shares of Amicus Therapeutics stock on the open market in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $7.00, for a total value of $35,000.00. Following the completion of the transaction, the vice president now directly owns 50,000 shares of the company’s stock, valued at approximately $350,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded down 1.10% during mid-day trading on Friday, hitting $7.19. The stock had a trading volume of 6,555,771 shares. Amicus Therapeutics has a 52 week low of $1.77 and a 52 week high of $7.52. The stock’s 50-day moving average is $4.63 and its 200-day moving average is $3.02. The company’s market cap is $565.9 million.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings data on Thursday, August 7th. The company reported ($0.31) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.08. On average, analysts predict that Amicus Therapeutics will post $-0.94 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Cowen and Company raised their price target on shares of Amicus Therapeutics to $14.00 in a research note on Wednesday, August 20th. Separately, analysts at Janney Montgomery Scott upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 1st. They now have a $5.00 price target on the stock, up previously from $2.50. Finally, analysts at Leerink Swann upgraded shares of Amicus Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 1st. They now have a $6.00 price target on the stock, up previously from $2.50.

Amicus Therapeutics, Inc (NASDAQ:FOLD) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.